On the HCPLive news page, resources on the topics of disease- and specialty-specific medical news and expert insight can be found. Content includes articles, interviews, videos, podcasts, and breaking news on health care research, treatment, and drug development.
Patients with Alopecia Areata Show Higher Prevalence of Autoimmune, Inflammatory DiseasesJune 9th 2023
Alopecia areata patients had higher rates of diseases including psoriasis, allergic rhinitis, asthma, and atopic dermatitis, highlighting the burden of comorbidities on patients in the US.
Metformin Could Reduce Long COVID Risk in People with Overweight or ObesityJune 9th 2023
Data from the COVID-OUT trial suggests use of metformin could reduce a person's risk of developing long COVID by more than 50% relative to placebo therapy, with results also providing insight into the apparent lack of benefit with ivermectin and fluvoxamine.
Biosimilars Month in Review: May 2023June 9th 2023
The biosimilars month in review highlights infliximab biosimilars data presented at Digestive Disease Week (DDW) 2023, California’s proposed plan to produce and market biosimilar insulin at production-equivalent prices, and new FDA approvals.
Shilpa Venkatachalam, PhD, MPH: Patient Perspectives of an Online Wellness Program for PsA ManagementJune 8th 2023
While most patients were interested in an online wellness program for managing their psoriatic arthritis, barriers, such as cost and fatigue, hindered their initiation of lifestyle adaptations.
Analysis Predicts Obesity as Leading Risk Factor for Heart Attacks by 2050June 8th 2023
An analysis of nationwide data in Singapore suggests obesity is set to become the leading metabolic risk factor underlying acute myocardial infarction onset, overtaking hypertension and hyperlipidemia in the coming decades.
Poor Air Quality Across the US: What You Need to KnowJune 8th 2023
Amid mass poor air quality exposure due to ongoing Canadian wildfires, Lungcast reviews air quality index, signs and symptoms of acute and long-term poor air exposure, high-risk patient populations, and the concerning future of particle pollution exposure.
Heart Attack During COVID Lockdowns Linked to Shorter Life ExpectancyJune 8th 2023
A decision-analytic model leveraging data from the UK and Spain suggests people who experienced STEMI during COVID-19 lockdown periods could have a reduced life expectancy relative to their counterparts who experienced similar events in prepandemic periods.
Early Guselkumab for Psoriasis: Increased Super-Responder Likelihood in Short Disease DurationJune 8th 2023
Early intervention was shown to lead to better clinical responses, results which could translate to long-term improvements in psoriasis and sustained maintenance of response after withdrawal.
Lack of Timely Follow-up Care After Heart Failure Common in Type 2 DiabetesJune 7th 2023
An analysis of Medicaid data from adults in Alabama suggests just more than 50% of patients fail to get ambulatory follow-up care within the recommended 14-day window following a first-time heart failure hospitalization.
Investigators Find 3 Novel Loci to Better Understand Genetic Factors of Sleep Apnea
CCDC3 has shown to repress inflammatory activity of TNF-alpha, a cytokine postulated involved in sleep regulation and MARCHF1 has shown to inhibit cellular insulin sensitivity and promotes NF-KB, with degree of activation positively correlating with OSA severity.
Newly-Developed Sulfa Antibiotic Allergy Clinical Decision Rule Shows Strong ResultsJune 7th 2023
Adaptation of penicillin allergy clinical decision tool PEN-FAST showed strong performance, indicating the potential utility of the tool for identifying patients with low-risk allergy phenotypes who may safely undergo direct oral challenges.
Patients With Psoriatic Arthritis Interested in Wellness Program, Although Barriers RemainJune 7th 2023
More than 90% of respondents reported being “somewhat likely” or “very likely” to speak with an online coach ≥2 per week or spend 1 – 2 hours per week learning about lifestyle behaviors if given the opportunity.
Strong Long-Term Trial Data for Adalimumab Observed for HS Patients in Real World SettingsJune 7th 2023
In the results of this final analysis, the hidradenitis suppurativa drug was found to be well tolerated in patients regardless of either differing demographics or clinical characteristics.